TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01681654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance Intervention
Description: Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance Intervention
Description: Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
Study: NCT03172871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: Aripiprazole IM depot 400 mg/300 mg (when not tolerated)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole IM Depot
Description: Aripiprazole IM depot 400 mg/300 mg (when not tolerated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole tablet
Description: Oral aripiprazole tablets 10 to 20 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole tablet
Description: Oral aripiprazole tablets 10 to 20 mg daily
Study: NCT02549807

Intervention type: DEVICE
Intervention: Muscle elasticity measure
Description: an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.

Intervention type: DEVICE
Intervention: Muscle elasticity measure
Description: an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.

Intervention type: DEVICE
Intervention: Muscle elasticity measure
Description: an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
Study: NCT03307603

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium-90 radioembolization
Description: Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib - nivolumab
Description: 240 mg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase II - nivolumab
Description: nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
Study: NCT04270149

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESR1 peptide vaccine
Description: ESR1 peptides plus Montanide and GM-CSF
Study: NCT04115514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation.
Description: Study Drug Administration:~* Dose/Volume- Liothyronine Sodium 50 mcg / 10 mL~* Frequency/Duration: Twice daily over 5 days (10 total doses), or until extubation, whichever comes first.~* Method: Instilled via a catheter through the ETT directly into the airway.

Intervention type: OTHER
Group type: OTHER
Intervention: Non-intervention
Description: Standard of Care (SOC)
Study: NCT04234204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fezolinetant
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT01009944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril, Atenolol
Description: once a day for 14 weeks
Study: NCT03106441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy by nasal cannula. Optiflow®
Description: Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial mask oxygenation in BIPAP ventilation
Description: Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
Study: NCT03601039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absnow Absorbable ASD Closure System
Description: the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
Study: NCT01293344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled nutritional intervention based on the Mediterranean diet
Description: Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled nutritional intervention based on the Mediterranean diet
Description: Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
Study: NCT01940367

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS (Percutaneous Tibial Nerve Stimulation
Description: PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Description: TENS therapy will be administered as follows:~* Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~* The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~  * Mode: Burst~ * Cycle: 10 seconds~ * Frequency: 10 Hz~ * Pulse Width: 250 µs~ * Intensity: to subject comfort level
Study: NCT01893411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (16 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (12 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (4 Units per kg body weight)
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
Study: NCT03916536

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium Laser
Description: Holmium laser enucleation of large sized prostate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thulium Laser
Description: Thulium laser enucleation of large sized prostate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar diathermy
Description: Bipolar enucleation of large sized prostate
Study: NCT01748188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
Study: NCT04533451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02712580

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: First investigational device
Description: The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Second investigational device
Description: The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ES Wetling W200 Placebo with white light
Description: The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ES Wetling W200 Placebo with red light
Description: The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
Study: NCT02643355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Study: NCT03868956

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colour doppler ultrasound with or without D-dimer test
Description: * Positive CDUS: anticoagulant treatment~* Negative CDUS: no anticoagulant treatment~* Non diagnostic CDUS : reference to routine D-dimer test~  * Negative test : no anticoagulant treatment~ * Positive test : second CDUS 7 days (±2) after first one~    * No change in CDUS : no anticoagulant treatment~   * Change in CDUS : anticoagulant treatment
Study: NCT01748188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
Study: NCT03750227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery
Study: NCT01748188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
Study: NCT03750227

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample, tissue and CSF sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample, tissue and CSF sample collection
Study: NCT03345563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Mind Training (BMT)
Description: Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Training (BT):
Description: Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care (UC)
Description: Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
Study: NCT03465579

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic MRI
Description: multi-parametric pelvic MRI

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic MRI
Description: multi-parametric pelvic MRI
Study: NCT01748188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
Study: NCT01454128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: 36 session supervised exercise intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: 36 session supervised exercise intervention
Study: NCT03079934

Intervention type: DEVICE
Intervention: Absorb-BVS
Description: BVS patients undergoing optical coherence tomography examination at follow-up
Study: NCT01716039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX 12.5
Description: once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX 25
Description: once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subjects will receive 18 weekly doses of adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subjects will receive 18 weekly doses of adalimumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Subjects will receive 18 weekly doses of adalimumab
Study: NCT03155087

Intervention type: DRUG
Intervention: Metformin
Study: NCT04668833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous lymphocyte infusion (ALI)
Description: On the day after completing the last dose of radiation therapy, the patient will have an appointment scheduled in the Apheresis Unit for the infusion of unmunipulated cryopreserved cells. Patients will be pre medicated with acetaminophen (325-650 mg PO) and diphenhydramine (12.5-25 mg PO or IV) prior to infusion. Cells will be infused without a leukoreduction filter at a rate determined by cell volume.
Study: NCT02895672

Intervention type: DRUG
Intervention: GLP-1 therapy
Description: The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.

Intervention type: DRUG
Intervention: GLP-1 therapy
Description: The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
Study: NCT04345029

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement consumption
Description: The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement consumption
Description: The experimental product consumption time was 60 days and the control consumption time was 60 days.~Each subject must consume both products, with a washing period of 30 days.
Study: NCT01015495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
Study: NCT01087658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Magnesium
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and Magnesium
Description: Intravenous